Pegvisomant. A last resort in acromegaly

Prescrire International

Volumn 14, Issue 75, 2005, Pages

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; GROWTH HORMONE; GROWTH HORMONE RECEPTOR; OCTREOTIDE; PEGVISOMANT; PLACEBO; SOMATOMEDIN; SOMATOSTATIN DERIVATIVE;

ACROMEGALY; ARTICLE; CLINICAL TRIAL; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG FORMULATION; DRUG INDICATION; DRUG MARKETING; DRUG RECEPTOR BINDING; DRUG RESPONSE; EVIDENCE BASED MEDICINE; HEADACHE; HORMONE DETERMINATION; HUMAN; HYPOPHYSIS ADENOMA; INSULIN SENSITIVITY; KIDNEY FUNCTION; LICENSING; LIVER FUNCTION; LIVER TOXICITY; PATIENT MONITORING; RADIOTHERAPY; SURGICAL TECHNIQUE; TREATMENT FAILURE; TUMOR VOLUME;

EID: 18144369626     PISSN: 11677422     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (6)

1. US Food and Drug Administration - Center for Drug Evaluation and Research "Application number 21-106 - Chemistry Review" 25 June 2001: 14 pages.
2. The European Agency for the Evaluation of Medicinal Products - Committee for Proprietary Medicinal Products - European Public Assessment Report (EPAR) "pegvisomant - Somaverto°" 17 February 2003: 103 pages.
3. US Food and Drug Administration - Center for Dmg Evaluation and Research "Application number 21-106 - Medical Review" 12 February 2003: 133 pages.
4. Trainer PJ et al. "Treatment of acromegaly with the growth hormone - receptor antagonist pegvisomant" N Engl J Med 2000; 342: 1171-1177.
5. Drake WM et al. "Successful treatment of resistant acromegaly with a growth hormone receptor antagonist" Eur J Endocrinol 2001; 145: 451-456.
6. Van der Lely A et al. "Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist" Lancet 2001; 358 (1295): 1754-1759.